Abstract
Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days.
In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment (VAS-work >50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test). In 144 users, there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001). This pilot study provides not only proof-of-concept data on the work impairment collected with the app but also data on the app itself, especially the distribution of responses for the VAS. This supports the interpretation that persons with rhinitis report both the presence and the absence of symptoms.
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| INTRODUCTION
Allergic rhinitis (AR), one of the most common diseases in the world, affects over 25% of the European population. 1 It exists in all age groups, often starts early in life and persists across the life cycle. AR often impairs social life, as well as school and work performance. Uncontrolled allergic and nonallergic rhinitis have a significant impact on work productivity. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) is used in many studies and has convincingly shown a significant negative effect on presenteeism in patients with moderate to severe AR. 9, 10 Rhinitis may impact work productivity to a greater extent than other chronic diseases such as diabetes, hypertension or asthma. 11, 12 The treatment of AR improves work productivity over time. [13] [14] [15] [16] [17] [18] [19] To date, however, studies have not collected data on productivity on a daily basis. Treatment of AR improves control and work productivity.
AR control includes symptom scores, patients' self-administered visual analogue scales (VASs), objective measures of nasal obstruction and patients' reported outcomes such as QOL or scores with several items. 20, 21 VAS was found to be an appropriate measure of self-assessed rhinitis control 22 and offers fine nuances of judgement, easy handling and good data quality. Also, it shows less distortion and bias than categorical scales. Moreover, continuous scores are well measured and statistically analysed by using VAS.
23
"Smart" devices and Internet-based applications are already used in rhinitis. [24] [25] [26] [27] [28] [29] [30] WPAI:AS questionnaire 9,10 in six EU countries and a daily VAS for work (VAS-work) in 21 countries. The Allergy Diary also collects daily VAS data for overall symptoms (VAS-global measured) and nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma).
| Aims
The primary aim of this cross-sectional study was to assess the impact on work productivity of uncontrolled rhinitis using VAS in all 21 countries, and WPAI:AS in the six countries where available.
2 | ME TH ODS
| Setting
The app is freely available in 16 languages and 21 countries (Table S1 ). 
| Users

| Allergy diary
The Allergy Diary collects information on the AR symptoms experienced (nasal and ocular), on how symptoms impact users' lives, and on type(s) of AR treatment used (Table S2) . Moreover, geolocalized users assess their daily symptom control using the touch screen functionality on their smart phone by clicking on five consecutive VAS measures (VAS-global measured, VAS-nasal, VAS-ocular, VAS-asthma and VAS-work). The system is deployed in 21 countries and 16 languages (translated and back-translated, culturally adapted and legally compliant). Daily AR treatments were also recorded.
| Ethics
The terms of use were translated into all relevant languages and customized according to the legislation of each country. This enabled the use of the results for research purposes.
The data were anonymized (no name or address recorded) except for geolocalized data to the area level. 35 The European Commission's Article 29 Working Party states that geolocation information is personal data (http://ec.europa.eu/newsroom/just/item-detail.cfm?item_ id=50083) and that information can be collected, shared or stored only with people's express consent. This is the case for MASK given that users agree to geolocation in the terms of use of the app.
Moreover, geolocation is optional : each user can allow it or not on his/her cell phone and it can be disallowed at any time. Finally, geolocation is not used in the data mining process and the phone IP is not retained.
Formal institutional board review and approval were not required for this study.
| Outcomes
Five VAS measurements (VAS-global measured, VAS-nasal, VAS-ocular, VAS-asthma and VAS-work, Table 1 , Figure S1 ) and a VAS-global calculated score (VAS-nasal + VAS-ocular divided by 2) were considered.
The WPAI:AS questionnaire was applied in the six available languages (English, French, German, Italian, Portuguese, Spanish).
9,10
The electronic form of the questionnaire was used according to the package obtained from Reilly and associates (www.reillyassociates.ne t/WPAI_General.html) ( Table S3 ). The percentage of impairment due to allergy while working (Q4/10) was the outcome used in the study.
| Biases
There are potential measurement biases when using apps as the information collected is usually restricted and less complete than when using lengthy paper or Web-based questionnaires. A bias might be introduced given that app users may be a selected subset and therefore not fully representative of all patients with rhinitis. The question was only applied to users reporting "yes" to the question "Do you have AR?"). The question was applied to users who indicated that they had "worked today".
T A B L E 1 Study outcome measures
c
With the question "Are you currently employed (working for pay)?"
Higher education or specific age ranges might apply. The study was not meant to be representative of the general population.
| Size of the study
In this exploratory pilot study, all registered users between 1 June and 31 October 2016 were included to obtain the best possible estimates for the specified time window. There were no exclusion criteria.
| Statistical methods
The proportion of users with baseline characteristics and the number of VAS days were described as percentages (for the full data set), by mean and standard deviation or median and interquartile range.
Some users reported VAS scores more than once per day. Before analysis, we proposed that if the same treatment was reported and the daily variation was under 30%, then the highest VAS score would be used. There were 1042 days with multiple values, and the variation was above 30% on only 70 days. We determined post hoc that this number was insufficient to impact the results, and we used the highest value for the day.
| Disease classification of users
We used Q1 and Q3 (Table S2) to define "allergic rhinitis", consistent with a previous study, showing that the impairment on activities was similar in subjects with Q1 "yes" and Q1 "no" + Q3 "yes".
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• Users with AR included those who reported the following:
• "I have AR" (Q1 , Table S1 ).
• "I do not have AR" (Q1) BUT who ticked any rhinitis symptoms at Q3 (Table S1 ). Conjunctivitis symptoms were not considered as defining AR.
• Users with no AR were those who reported "no" for Q1 AND ticked no relevant symptom for Q3.
The independency of VAS questions was assessed using the Bland and Altman regression analysis.
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A contingency table was made using cut-offs proposed by a previous consensus on AR control: 22 1. VAS score <20: fully productive at work or well-controlled AR.
2. VAS score 20-50: partly productive at work or partly controlled AR.
3. VAS score >50: poorly productive at work or uncontrolled AR.
The mean square contingency coefficient Phi was computed.
Correlations including "allergic rhinitis" users were made using the Spearman's rank test. As there may be interactions between multiple observations for the same user, we started by comparing the first day of VAS and then, separately, all days with VAS. The following correlations were made:
4. VAS-global calculated and VAS-work (co-primary end point).
VAS-global measured and VAS-work (co-primary end point).
6. VAS-nose and VAS-work.
VAS-ocular s and VAS-work.
VAS-asthma and VAS-work.
The statistically significant correlations were ascribed to "very strong" (Rho ranging from 0.80 to 1.00), "strong" (Rho 0.60 to <0.80)
or "moderate" (Rho ranging from 0.40 to <0.60). 37 
| Exploratory analyses
We used the Spearman's rank test to correlate WPAI:AS with VAS-global calculated and VAS-work. However, WPAI:AS estimates work productivity during 7 days before measurement, and the app analysed events on the day of WPAI:AS assessment and after.
For this analysis, we selected Q4-WPAI and the baseline day of VAS.
3 | RESULTS
| Users
A total of 1120 users completed app responses on 5889 days for VAS-work. 1086 users responded "yes" to Q1 and 34 responded "no" to Q1 but nonetheless ticked at least one nasal symptom (Q3).
Only 16 users reported "no allergic rhinitis" making comparisons with The phenotypic characteristics of the users are provided in Table S4 .
The treatments received included a wide range of over-thecounter (OTC) and prescribed AR medications, and there was no consistent pattern upon which to base any relevant comparisons.
| VAS scores
The mean values for the first day reported and all reported days are similar ( Table 2 ). In the 5789 VAS days of "allergic rhinitis" users ( Figure S2 ), VAS scores show that for 61% of days, the symptoms of allergic rhinitis were well controlled (VAS-global measured or calculated <20) (Table 1; Figure S2 ). Uncontrolled rhinitis was observed for 39% of days. Few users reported uncontrolled asthma. VAS-work was <20 in 66% of days, between 20 and 50 in 20% of days and over 50 in 14% of days.
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| Independence between the VAS scores
The Bland and Altman regression analyses showed that all VAS measurements were independent (P<0.05 for all comparisons) and that correlations could therefore be estimated appropriately (Table S5 , Figure S3 ).
| Correlations between VAS scores for disease control
There was a highly significant correlation between VAS-global measured and VAS-global calculated for the first day of the survey (N=1086, Rho=0.84, Figure S4a ) and for all days (N=5678, Rho=0.89, Figure S4b ).
| Correlations between VAS scores for work and disease control
A contingency table was made using VAS score cut-offs of 20 and 50 (Table 3) . Less than 20% of days with controlled disease (VAS<20) were associated with work impairment. On the other hand, over 97% of days with uncontrolled disease (VAS≥50) were associated with work impairment.
Using the Spearman's rank correlation, there was a very strong correlation between VAS-work and VAS-global (measured or calculated), a strong correlation between VAS-work and VAS-ocular and a moderate correlation between VAS-work and VAS-asthma (Table 4 , Figure 1 ; Figure S5 ).
| Correlations between VAS and WPAI:AS
There was a moderate correlation between Q4-WPAI:AS and VASwork (N=195, Rho=0.45) and VAS-global measured (N=195, rho=0.42) (Tables 2 and 4, Figure S6 ). Although numbers were small, when VAS-work was >40, WPAI-AS was always impaired.
| DISCUSSION
A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) was used to collect daily visual analogue scale (VAS) data for allergic symptoms and work (VAS-work) in 21 countries. This pilot study provides not only proof-of-concept data on the work impairment collected using an app, but also data on the app performance itself. The distribution of answers of the VAS indicates that patients adequately report not only the absence of symptoms but also severe impairment. Most days with uncontrolled rhinitis were associated with impaired work. There was an association with WPAI:AS in a small data set (144 users).
| Strengths and limitations
Smart devices and Internet-based applications are already used in rhinitis, [24] [25] [26] [27] [28] [29] but none have assessed work productivity. The strengths of the mobile technology include its wide acceptance and easy use. However there is a need to use appropriate questions, and results should be assessed by pilot studies. This pilot study was based on 1136 users who filled in 5789 days of VAS, allowing us to perform comparisons among outcomes, but not to make subgroup analyses.
We collected country, language, age, sex and date of entry of information. We used very simple questions translated and backtranslated into 16 languages. We did not check accuracy or the time taken to complete the survey. An additional bias may be introduced by countries with high versus low numbers of participants.
The app is not designed to compare AR patients with control subjects, and this was not a clinical trial. Thus, as expected, over 98% of users reported "AR" and we are unable to assess the responses of "non-AR" users. On the other hand, there are many days with no symptoms in a sufficient number of persons with AR to allow comparisons between outcomes for those with more or less symptoms.
In this study, statistical hypothesis testing was carried out assessing differences in frequency distributions between groups as well as pairwise correlations. We used both the first observation for all users and multiple observations from the same individual, even though the latter are not independent observations from the same individual. This can be addressed in future confirmatory analyses with larger data sets using a repeated-measures approach.
Medical treatments used by each participant were recorded, but we did not attempt to assess the effect of any treatment on VASwork for two major reasons. Firstly, disease control is independent T A B L E 2 VAS and Q4-WPAI:AS scores 
| Interpretation of the results and generalizability
Symptoms of AR are highly variable depending on allergen exposure and treatments received. Moreover, the duration of the use of the app was variable (from 1 day to over a month). We therefore compared results by day rather than by user. There were strong to very strong correlations between the overall control of rhinitis and work VAS. We used two methods to assess overall control (measured and calculated from nasal and ocular symptoms), and the correlations were similar. In days with uncontrolled rhinitis, less than 11% were associated with no work impairment and over 50% were associated with severe work impairment.
We then attempted to correlate VAS with a validated questionnaire. However, the comparison between a 7-day instrument (WPAI:AS) and a single day of VAS may not be fully relevant and, as the WPAI:AS was only available in six languages, only 195
users were recorded. We may have used a 7-day prospective analysis, but WPAI:AS is relevant to the past 7 days. We found a significant correlation between Q4 (work productivity) and VASwork or measured global VAS. The mean scores of Q4-WPAI:AS are relatively low by comparison with published studies and suggest that some rhinitis users may have a mild disease. This is confirmed by the VAS-nasal levels.
The results of this pilot study confirm previous studies indicating that AR impacts work productivity. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, this is the first study using an app to allow a daily evaluation. Moreover, it shows F I G U R E 1 Correlation between VAS-work and VAS-global calculated the close relationship between work impairment and AR severity or control. 9, 40 These results indicate that a simple VAS measurement of work status using an app can be a useful measure of daily work productivity. Such a tool is likely to be of great importance for the assessment of the indirect costs incurred by AR and the benefits from therapeutic interventions. Moreover, the question on VASwork can be used for other chronic diseases allowing comparisons of public health interest.
The economic impact of the loss of work productivity is an essential component to consider. It has been estimated that the socio-economic costs throughout the EU for undertreated allergic airway diseases are up to 100 b€ annually. 41 The costs due to work impairment will be assessed using the Allergy Diary once further data are available, as EQ-5D 42 is included in the app.
| CONCLUSIONS
This pilot study in a large number of users in 21 countries shows the impact of uncontrolled rhinitis in work. It also confirms previous data that consistently indicate such an effect using a variety of methods. The technology employed in this study is unique as it can provide data collected on a daily basis in a large sample and over a wide geographic, cultural and linguistic distribution. In summary, this novel technology allows researchers to consider potential new strategies assessing the burden of AR and, potentially, its optimal management.
